标题
Panobinostat in lymphoid and myeloid malignancies
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 22, Issue 9, Pages 1211-1223
出版商
Informa Healthcare
发表日期
2013-07-03
DOI
10.1517/13543784.2013.815165
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia
- (2013) I. M. Ghobrial et al. BLOOD
- A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
- (2013) John Mascarenhas et al. BRITISH JOURNAL OF HAEMATOLOGY
- Proteasome inhibitors in multiple myeloma: 10 years later
- (2012) P. Moreau et al. BLOOD
- Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
- (2012) Sally Clive et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Romidepsin for Cutaneous T-cell Lymphoma
- (2012) H. M. Prince et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
- (2012) Donna M. Weber et al. Clinical Lymphoma Myeloma & Leukemia
- Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
- (2012) Madeleine Duvic et al. EUROPEAN JOURNAL OF CANCER
- Panobinostat for the treatment of multiple myeloma
- (2012) Paola Neri et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Predicting survival in chronic lymphocytic leukemia
- (2012) Ali Bazargan et al. Expert Review of Anticancer Therapy
- A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
- (2012) Akira Fukutomi et al. INVESTIGATIONAL NEW DRUGS
- Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- (2012) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia
- (2012) A Vilas-Zornoza et al. LEUKEMIA
- Targeting Epigenetic Readers in Cancer
- (2012) Mark A. Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
- (2011) R. L. Piekarz et al. BLOOD
- Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia
- (2011) M. J. Bishton et al. BLOOD
- Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007
- (2011) G. M. Dores et al. BLOOD
- Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
- (2011) R. B. Walter et al. HAEMATOLOGICA
- Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
- (2011) Sachi Morita et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
- (2011) Mark Kirschbaum et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517
- (2011) Mark H. Kirschbaum et al. LEUKEMIA & LYMPHOMA
- Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
- (2011) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- (2011) J. W. Friedberg Hematology-American Society of Hematology Education Program
- MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi)
- (2010) Kate L. Burbury et al. ANNALS OF HEMATOLOGY
- Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
- (2010) M. Sant et al. BLOOD
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Epigenetic therapy of lymphoma using histone deacetylase inhibitors
- (2010) Maribel Cotto et al. Clinical & Translational Oncology
- Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia – a report of five cases
- (2010) Hanne Fredly et al. Hematology
- Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
- (2010) Michael Dickinson et al. INVESTIGATIONAL NEW DRUGS
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
- (2009) Michael Dickinson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes
- (2009) S. Hauswald et al. CLINICAL CANCER RESEARCH
- Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors
- (2009) H Miles Prince et al. Future Oncology
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
- (2009) E. M. Ocio et al. HAEMATOLOGICA
- A phase 2 study of vorinostat in acute myeloid leukemia
- (2009) E. W. Schaefer et al. HAEMATOLOGICA
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
- (2008) M. Crump et al. ANNALS OF ONCOLOGY
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
- (2008) L. Ellis et al. CLINICAL CANCER RESEARCH
- Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia
- (2008) A. Kalff et al. HAEMATOLOGICA
- The Long Road to a Cure for Acute Myelocytic Leukemia: From Intensity to Specificity
- (2008) William P. Vaughan et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinically Relevant QTc Prolongation Is Not Associated With Current Dose Schedules of LBH589 (panobinostat)
- (2008) Lei Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes
- (2008) JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
- (2008) Paul Richardson et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started